This hypothesis arises from our recent findings showing that BCR-ABL from CML myeloid DCs mediates iNKT-cell immune subversion by downregulating cell-surface CD1d expression (27). This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.